[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:notch1-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"NOTCH1 Gene",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06357676","Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:02.712396Z","2026-05-05T02:43:28.817702Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06846463","Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",[19],"Phase 2","2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.810232Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[19],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06315309","Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant",[19],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:29.662218Z"]